|Articles|April 2, 2009

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular R
Volume 15
Issue 3

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Download PDF: Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Articles in this issue

almost 17 years ago

Article

Beyond LDL Cholesterol: The Role of Elevated Triglycerides and Low HDL Cholesterol in Residual CVD Risk Remaining After Statin Therapy

almost 17 years ago

Article

Introduction

almost 17 years ago

Article

Participating Faculty

almost 17 years ago

Article

The Impact of Residual CVD Risk in the Managed Care Setting

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

ByMohamed M. Ali, MS,Scott Lunos, MS,Zachary Henderson, BSB,Michele Allen, MD, MS,Patricia Adam, MD, MSPH,Genevieve B. Melton, MD, PhD,Rubina Rizvi, MD, PhD

January 12th 2026

Subjective and Objective Impacts of Ambulatory AI Scribes

ByJulia Adler-Milstein, PhD,Orianna DeMasi, PhD,Hossein Soleimani, PhD,Sarah Beck, MDiv,Maria E. Byron, MD,Aris Oates, MD,Robert Thombley, BS,Jinoos Yazdany, MD, MPH,Sara G. Murray, MD, MAS

January 8th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Articles in this issue

Newsletter

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

Subjective and Objective Impacts of Ambulatory AI Scribes

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Highlighting Gaps in Allergic Rhinitis Care, Allergen Immunotherapy Access

Novel CLL Therapies Prompt New Treatment Considerations

Congress Unveils Massive Funding Bill to Avert Shutdown

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD